首页|Mechanisms of Shufeng Jiedu Capsule in treating bacterial pneumonia based on network pharmacology and experimental verification
Mechanisms of Shufeng Jiedu Capsule in treating bacterial pneumonia based on network pharmacology and experimental verification
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
万方数据
Objective:The aim of this study was to investigate the underlying mechanism of Shufeng Jiedu Capsule(SFJD)for treating bacterial pneumonia(BP)in vivo based on network pharmacology and experimental verification study.Methods:Network pharmacology was used to screen the active compounds and target genes of SFJD.Then,the multi drug resistance-Pseudomonas aeruginosa(MDR-PA)mice lethal model and MDR-PA pneu-monia model were established to evaluate the therapeutic effects and underlying mechanisms of SFJD.Western blot and ELISA were used to determinate the protein expression level of the IL-17 signaling path-way and JAK/STAT signaling pathway.Results:After screening,172 potential components of SFJD were generated,based on which we con-structed an SFJD-component-target-BP interaction network.The Gene ontology(GO)and Kyoto encyclo-pedia of genes and genomes(KEGG)enrichment revealed that SFJD could regulate the IL-17 signaling pathway and Janus kinase/signal transducer and activator of transcription(JAK/STAT)signaling pathway.Molecular docking showed that the potential target proteins had good combinations with the main active components.SFJD significantly reduced the mortality and prolonged survival days in lethal models.The lung index and pathological changes in the lung were also significantly decreased.SFJD could signifi-cantly decrease the expression of interleukin-17A(IL-17A),TNF receptor associated factor 6(TRAF6),phospho-inhibitor of nuclear factor-kappa B(p-IKB)/inhibitor of NF-κB(IκB),phospho-NF-κB p65(p-NF-κB p65),phospho-protein kinase B(p-AKT)/AKT,phospho-signal transducer and activator of tran-scription 3(p-STAT3)/STAT3,phospho-signal transducer and activator of transcription 1(p-STAT1)/STAT1,and the protein level of interleukin-6(IL-6),tumor necrosis factor α(TNF-α),and IL-1β.Conclusion:Combined with network pharmacology and in vivo study,it was found that SFJD exerted its therapeutic effects on BP by inhibiting the IL-17 pathway and JAK/STAT signaling pathway.This study provides new evidence for SFJD in treatment of BP.
NETL
NSTL
万方数据
